Please login to the form below

Not currently logged in
Email:
Password:

Oramed completes USD 2m financing round

Oramed Pharmaceuticals, an Israeli-headquartered developer of oral insulin gel capsules, has closed a financing round of over USD 2m by private investors.

Oramed Pharmaceuticals, an Israeli-headquartered developer of oral insulin gel capsules, has closed a financing round of over USD 2m by private investors.

The placement was at USD 0.50 per share with a warrant priced at USD 0.75.

Oramed's CEO, Nadav Kidron, said: "This investment, at a premium to the market, ensures that Oramed has enough funds to reach completion of phase I trials, which we expect by mid-2008. We hope to complete our phase Ia trials shortly. This investment...allows the company to fully focus on its R&D efforts and complete its phase I product trials."

Oramed is currently developing an orally ingestible soft gel insulin capsule for the treatment of diabetes. The company says it is also pursuing the development of oral delivery solutions for other drugs and vaccines.

6th August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics